GeneDx Holdings Corp. (WGS)
Official siteHEALTHCARE • DIAGNOSTICS & RESEARCH • NASDAQ
Market Cap: $1.53B
Last updated: Nov 17, 2026 at 4:32 PM ET
GeneDx Holdings Corp. (WGS) Statistics
GeneDx Holdings (WGS) has a market cap of $1.53B and an enterprise value of $1.64B. It kept -24.10% of revenue as net income over the last 12 months. Its share count is up 3.76% from a year earlier.
Total Valuation
Enterprise value is 7.42% above the market cap, as debt exceeds cash.
| Market Cap | $1.53B |
|---|---|
| Enterprise Value | $1.64B |
| Latest price (Nov 17, 2026) | $47.29 |
Key Dates
The next earnings report is set for Feb 22, 2027, after the close.
| Next Earnings Date | Feb 22, 2027, after the close |
|---|---|
| Last Earnings Date | Nov 9, 2026 |
| Fiscal Year End | December |
Valuation Ratios
Sales and book value multiples are 3.1x and 5.8x.
| P/E Ratio | 315.3x |
|---|---|
| Forward P/E | 468.2x |
| P/S Ratio | 3.1x |
| Forward P/S | 3.2x |
| P/B Ratio | 5.8x |
| P/TBV Ratio | 13.4x |
| PEG Ratio | 8.3 |
Price Statistics
The stock is down 63.07% over 52 weeks and trades 34.65% below its 50-day average.
| Beta (1Y) | 1.63 |
|---|---|
| 52-Week Change | -63.07% |
| 1-Month Change | -28.66% |
| 3-Month Change | -40.63% |
| 6-Month Change | +12.25% |
| 5-Year Change | -74.07% |
| Total Return (1Y) | -63.07% |
| Total Return (3Y CAGR) | +209.10% |
| Total Return (5Y CAGR) | -27.32% |
| Return vs SPY (1Y) | -74.30% |
| Max Drawdown (1Y) | -79.40% |
| Max Drawdown (3Y) | -79.40% |
| Sharpe Ratio (1Y) | -0.97 |
| Correlation with SPY (1Y) | 0.22 |
| 50-Day Average | $72.36 |
| 200-Day Average | $69.41 |
| 52-Week Range | $32.21 to $170.87 |
| RSI (14 Days) | 32.0 |
| Average Volume (20 Days) | 1.20M |
The 5-year change compares month-end closes, adjusted for splits, through Oct 2026.
Financial Position
Current assets cover 4.16x current liabilities, and total debt is 0.86x shareholder equity.
| Current Ratio | 4.16x |
|---|---|
| Quick Ratio | 3.85x |
| Debt / Equity | 0.86x |
Returns and Efficiency
Return on invested capital is -22.08% over the last 12 months, against a 5-year average of -4.48%.
| Return on Equity (ROE) | -45.38% |
|---|---|
| Return on Assets (ROA) | -21.09% |
| Return on Invested Capital (ROIC) | -22.08% |
| Return on Capital Employed (ROCE) | -22.07% |
| ROE (5Y Average) | -76.97% |
| ROA (5Y Average) | -42.91% |
| ROIC (5Y Average) | -4.48% |
| Asset Turnover | 0.90x |
| Inventory Turnover | 7.29x |
| Receivables Turnover | 5.24x |
| Cash Conversion Cycle | 25 days |
Scores
WGS has an Altman Z-Score of -0.13, in the distress zone below 1.81, and a Piotroski F-Score of 6 of 9, in the average band of 3 to 7.
Altman Z-ScoreDistress below 1.81Safe above 2.99
Piotroski F-ScoreWeak at 2 or lessStrong at 8 or more
| Altman Z-Score | -0.13 |
|---|---|
| Altman Z Zone | Distress |
| Piotroski F-Score | 6 of 9 |
| Piotroski Strength | Average |
Income Statement
Revenue of $460.78M over the last 12 months is up 14.57% from the 12 months before.
| Revenue | $460.78M |
|---|---|
| Revenue Growth (YoY) | +14.57% |
| Gross Profit | $316.78M |
| Operating Income | -$99.59M |
| Pretax Income | -$111.21M |
| Net Income | -$111.05M |
| EBITDA | -$73.14M |
| EBIT | -$100.44M |
| Reported EPS (TTM) | $0.15 |
Trailing 12 months through Sep 30, 2026.
Balance Sheet
Shareholder equity funds 46.48% of the $526.48M in total assets.
| Cash and Equivalents | $96.14M |
|---|---|
| Total Debt | $209.56M |
| Net Debt | $113.42M |
| Net Debt Per Share | $3.80 |
| Working Capital | $225.49M |
| Shareholder Equity | $244.69M |
| Book Value Per Share | $8.19 |
| Tangible Book Value | $105.32M |
| Tangible Book Per Share | $3.52 |
| Total Assets | $526.48M |
| Total Liabilities | $281.80M |
Balance sheet as of Sep 30, 2026.
Cash Flow
After $26.14M of capital spending, operating cash flow left -$101.22M of free cash flow.
| Operating Cash Flow | -$75.08M |
|---|---|
| Capital Expenditures | $26.14M |
| Free Cash Flow | -$101.22M |
| FCF Per Share | -$3.39 |
| Depreciation and Amortization | $27.30M |
Trailing 12 months through Sep 30, 2026.
Margins
The operating margin is -21.61%.
| Gross Margin | 68.75% |
|---|---|
| Operating Margin | -21.61% |
| Pretax Margin | -24.13% |
| Net Margin | -24.10% |
| EBITDA Margin | -15.87% |
| EBIT Margin | -21.80% |
| FCF Margin | -21.97% |
| Gross Margin (5Y Average) | 31.72% |
| Net Margin (5Y Average) | -91.67% |
Growth
Revenue grew 22.13% a year over 3 years.
| Revenue Growth (3Y CAGR) | +22.13% |
|---|---|
| Revenue Growth (5Y CAGR) | +18.98% |
| Book Value Per Share Growth (2Y CAGR) | +14.27% |
| Tangible Book Per Share Growth (2Y CAGR) | +48.35% |
Dividends and Yields
WGS does not pay a dividend. Its free cash flow yield is -7.16%.
| Earnings Yield | 0.32% |
|---|---|
| FCF Yield | -7.16% |
| Buyback Yield | -2.13% |
| Shareholder Yield | -2.13% |
Stock Splits
The last split was a 1-for-33 reverse split on May 4, 2023.
| Last Split Date | May 4, 2023 |
|---|---|
| Split Type | Reverse split |
| Split Ratio | 1:33 |
Analyst Forecast
Consensus estimates put revenue growth at 15.43% and EPS growth at -5.26% a year over the next 2 fiscal years.
| Revenue Growth Forecast (2Y CAGR) | +15.43% |
|---|---|
| EPS Growth Forecast (2Y CAGR) | -5.26% |
Price Target
Analyst price targets are part of paid GNG plans. See plans
GNG Valuation
| GNG view | Overvalued |
|---|
GNG fair value is part of GNG Pro. See plans
Frequently Asked Questions About WGS
What is WGS's market cap?
GeneDx Holdings has a market cap of $1.53B. Its enterprise value, which adds debt and subtracts cash, is $1.64B.
What is WGS's P/E ratio?
GeneDx Holdings has a trailing P/E ratio of 315.3x and a forward P/E of 468.2x.
How many shares of WGS are outstanding?
GeneDx Holdings has 29.88M shares outstanding. The count is up 3.76% from a year earlier.
Does WGS pay a dividend?
No. GeneDx Holdings does not pay a dividend.
How much debt does WGS have?
GeneDx Holdings has $209.56M of total debt and $96.14M of cash and equivalents, a net debt position of $113.42M.
WGS pages: Overview, Charting, Earnings, Forecast, Financials, Statistics, Valuation